This website uses cookies

Read our Privacy policy and Terms of use for more information.

In partnership with

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

✅ The Good News ✅

THE GOOD
Approvals & Labels

Pfizer's Hympavzi (marstacimab), targeting blood clotting protein, approved by MHRA for hemophilia A and B patients aged 12+ weighing over 35kg
Monoclonal antibody, hemophilia - Read more [Paywall]

THE GOOD
Business Development

Ypsomed sells diabetes business to TecMed for $513M, shifts focus to self-injectors, including GLP-1 medications
Medical device, injectables, drug delivery, insulin pump - Read more

Learn AI in 5 minutes a day

This is the easiest way for a busy person wanting to learn AI in as little time as possible:

  1. Sign up for The Rundown AI newsletter

  2. They send you 5-minute email updates on the latest AI news and how to use it

  3. You learn how to become 2x more productive by leveraging AI

✅ More Good News ✅

THE GOOD
Clinical Trials

Summit Therapeutics and Akeso's ivonescimab, targeting PD-1 and VEGF, shows improved progression-free survival over Tevimbra in Ph3 trial for non-small cell lung cancer
Bispecific antibody, lung cancer - Read more

THE GOOD
Company Launches

Synthetic Design Lab emerged from stealth with $20M to develop ADCs with 10-fold better payload delivery efficiency
Antibody-drug conjugate (ADC), drug development, drug discovery, AI, drug design - Read more

THE GOOD
Fundraises

Claris Ventures first closing of targeted €100M ($114M) biotech fund, financing early-stage Italian biotech startups
Venture capital, life science investment, biotech Investing - Read more

Grove Biopharma $30M Series A, advancing Bionic Biologics platform targeting intractable intracellular disease in oncology
Bionic Biologics, biologic, drug design, AI, drug discovery, drug development - Read more

Rezolute $90M public offering, developing novel therapies for hyperinsulinism-caused hypoglycemia with antibody therapy ersodetug
Monoclonal antibody, hypoglycemia, hyperinsulinism - Read more

Cytovation raises $6M to advance CY-101 Phase 2 trial for adrenocortical carcinoma with readouts expected 2026.
Protein, peptide, bifunctional peptide, cancer, adrenocortical carcinoma - Read more

Noveome Biotherapeutics $51M Series E, developing biologics for treating Necrotizing Enterocolitis and promoting cellular integrity.
Biological secretome, necrotizing enterocolitis - Read more

THE GOOD
Marketing

Vevo Therapeutics rebrands as Tahoe Therapeutics after name conflict, choosing to invest in cancer research rather than legal battles
Name change - Read more

THE GOOD
Mergers & Acquisitions

Swiss oncology firm Veraxa Biotech going public on Nasdaq via $1.6bn SPAC merger with Voyager Acquisition
Antibody-drug conjugate (ADC), bispecific T-cell engager, cancer, solid tumor, leukemia - Read more

THE GOOD
Partnerships

Repertoire, Genentech, collaborating to develop T cell-targeted therapies for autoimmune disease with $35M upfront payment
Platform technology, drug discovery, drug development, autoimmune disease - Read more

Boehringer Ingelheim, Tessellate Bio partnership to develop oral treatments for ALT-positive tumors using synthetic lethality approach
Drug development, cancer - Read more

Epicrispr Biotechnologies, Springbok Analytics partnering to evaluate AI muscle imaging as potential biomarker for FSHD therapy approval.
Biomarker, AI, imaging, facioscapulohumeral muscular dystrophy, gene therapy, adeno-associated virus (AAV), drug development - Read more

Tempus AI, AstraZeneca, Pathos AI partnering on $200M multimodal AI framework for oncology drug development and personalized medicine
AI, AI Training data, cancer, drug development, drug discovery - Read more

Bayer, ConcertAI multi-year partnership using AI/ML solutions and Translational360 to accelerate precision oncology clinical development
Small molecule, drug development, clinical development, AI, machine Learning, software, precision medicine - Read more

THE GOOD
Public Health

Pharmaceutical giants affirm long-term commitment to vaccine development despite increasing scrutiny in US market
Vaccine, drug development, pandemic preparedness, vaccine hesitancy - Read more [Paywall]

THE GOOD
Regulatory

Food companies to eliminate eight synthetic dyes from US products by 2026
Synthetic dyes, consumer health - Read more [Paywall]

❌ The Bad News ❌

THE BAD
Business Development

Sanofi returns cancer drug SAR443579 to Innate Pharma, redirects partnership focus from oncology to autoimmune diseases
NK cell engager, myeloid leukemia, cancer, autoimmune disease - Read more

THE BAD
Lawsuits

Eli Lilly sues four telehealth companies for selling unauthorized tirzepatide versions, following earlier lawsuits against compounding pharmacies
GLP-1, telehealth, obesity, compounding, copycat drug suit - Read more

THE BAD
Layoffs

Illumina to lay off 172 San Diego employees by mid-June, according to state WARN notice
Next-generation sequencing (NGS) - Read more [Paywall]

THE BAD
Opinions

AstraZeneca CEO warns Europe risks losing healthcare sovereignty due to lower pharmaceutical investment compared to US
Geopolitics, biotech ecosystem - Read more

THE BAD
Politics & Policy

Novartis and Sanofi CEOs urge EU to increase drug prices as Trump considers price parity with Europe
Drug Pricing, drug access - Read more

👹 The Ugly News 👹

THE UGLY
Politics & Policy

Women's Health Initiative, which revolutionized menopause and osteoporosis treatments, will lose federal funding in September
Women's health, federal funding - Read more [Paywall]

THE UGLY
Public Health

Survey finds partisan divide on measles awareness and vaccine safety, as misinformation spreads during nationwide outbreak
Vaccine, measles, infectious disease, vaccine hesitancy - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

Dance Thursday GIF by Sealed With A GIF

Gif: SWAG on Giphy

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here